EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Plus Therapeutics's enterprise value is $2.88 Mil.
Plus Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil. Therefore, Plus Therapeutics's EV-to-Revenue for today is .
The historical rank and industry rank for Plus Therapeutics's EV-to-Revenue or its related term are showing as below:
During the past 13 years, the highest EV-to-Revenue of Plus Therapeutics was 89.41. The lowest was -36.52. And the median was 3.17.
PSTV's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.68 * Ranked among companies with meaningful EV-to-Revenue only.
The historical data trend for Plus Therapeutics's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Plus Therapeutics's EV-to-Revenue
For the Biotechnology subindustry, Plus Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Plus Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Plus Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Plus Therapeutics's EV-to-Revenue falls into.
Plus Therapeutics's current Enterprise Value is $2.88 Mil.
Plus Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Plus Therapeutics (NAS:PSTV) EV-to-Revenue Explanation
Plus Therapeutics's share price for today is $1.6701.
Plus Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Plus Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Plus Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Plus Therapeutics (Plus Therapeutics) Business Description
Plus Therapeutics Inc is a clinical-stage pharmaceutical company. The company focused on the discovery, development, and delivery of complex and innovative treatments for patients battling cancer and rare diseases. Its product pipeline includes Patented RNL and Patented DocePLUS.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PSTV has been successfully added to your 